Castle Biosciences (CSTL) Net Cash Flow (2018 - 2026)

Castle Biosciences has disclosed Net Cash Flow across 9 years of filings, most recently posting -$53.0 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$53.0 million, down 76.43% year-over-year; the trailing twelve-month figure through Mar 2026 was -$25.9 million (down 484.64% YoY), and the FY2025 annual result was -$3.0 million, down 114.28% from the prior year.
• Net Cash Flow came in at -$53.0 million for Q1 2026 at Castle Biosciences, down from $31.2 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $31.2 million in Q4 2025 to a low of -$139.0 million in Q3 2022.
• The 5-year median for Net Cash Flow is -$8.1 million (2023), against an average of -$15.6 million.
• Across the five-year window, Net Cash Flow slumped 2592.48% in 2022 and surged 301.83% in 2024, its largest moves.
• Castle Biosciences' Net Cash Flow stood at -$11.2 million in 2022, then soared by 167.82% to $7.6 million in 2023, then soared by 224.89% to $24.8 million in 2024, then advanced by 25.95% to $31.2 million in 2025, then slumped by 269.91% to -$53.0 million in 2026.
• The last three Net Cash Flow figures came in at -$53.0 million (Q1 2026), $31.2 million (Q4 2025), and $3.3 million (Q3 2025), per Business Quant data.